Fact CheckerSign in

NCT07698054Not yet recruitingPhase 2

Toripalimab Combined With Beat Chemotherapy in the Treatment of Advanced Back-line Small Cell Lung Cancer

A Prospective, Open-label, Bayesian Adaptive Randomized Phase II Clinical Study of Toripalimab Combined With Beat Chemotherapy in the Treatment of Advanced Back-line Small Cell Lung Cancer

Source: ClinicalTrials.gov · Last updated 13 Jul 2026

Brief summary (registry, in English)

This study is a randomized, open-label, multi-center investigator-initiated clinical trial. Patients who meet the inclusion criteria receive the treatment plan stipulated in the protocol. A Bayesian design is used to explore the efficacy and safety of teprotumumab combined with pulse chemotherapy in the treatment of advanced second-line extensive-stage small cell lung cancer.

Status (registry)
Not yet recruiting
Phase (registry)
Phase 2
Study type
Interventional
Enrollment
130 (estimated)
First submitted
6 May 2026
Start date
1 Aug 2026
Primary completion date
1 Jan 2030
Lead sponsor
Henan Cancer Hospital
Diseases
Lung cancer
NCT number
NCT07698054

What you commit to

  • Study type: Interventional · Phase 2
  • Planned participants: 130
  • From 1 Aug 2026 to the primary completion date, 1 Jan 2030
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • 1.Those who are allergic to toripalimab or etoposide or have metabolic disorders;

Other

  • 2.With known the special ripley sheet resistance, etoposide contraindication;
  • 3.Other circumstances that the researcher assessed as unsuitable for participation in this clinical study.

Who the study is looking for

  • 1.Age ≥18 years old, both male and female are acceptable.
  • 2\. Histology and pathology diagnosis of extensive stage small cell lung cancer, and must meet the following standards:
    • always has not received the immune therapy,
    • Previously received immunotherapy, with the number of treatment lines ≥2 and the immunotherapy being effective(immunotherapy PFS \> 3 months, withdrawal time \> 3 months)
    • never used anlotinib,
  • 3\. ECOG: 0 \~ 2;
  • 4 . The expected lifetime 12 weeks or more;
  • 5\. Major organs function normal

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.